Pacira to Report 2024 Financial Results on Thursday February 27, 2025

Core Viewpoint - Pacira BioSciences, Inc. is set to report its fourth quarter and full year financial results for 2024 on February 27, 2025, after U.S. market close, followed by a live conference call [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL®: a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA®: an extended-release injection for osteoarthritis knee pain management [3] - ioveraº®: a handheld device providing immediate, long-acting, drug-free pain control through cold temperature [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]